Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Burlon

Internal Medicine Columbus, OH Doctor of Osteopathy

NPI 1306882634 CMS profile 195070

100 North Murray Hill Rd, Columbus, OH 43228

Open in the dashboard

General payments

$11,405

795 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Burlon of Columbus, OH is reported in the CMS Open Payments database as having received $11,405 across 795 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,685 90
2024 General $1,848 105
2023 General $1,780 88
2022 General $1,424 81
2021 General $1,712 142
2020 General $1,323 103
2019 General $1,634 186

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Burlon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Daniel Burlon were reported at $1,685. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Daniel Burlon Internal Medicine median Middle half National median
2019 $1,634 $159 $48–$570 $163
2020 $1,323 $119 $33–$402 $114
2021 $1,712 $135 $37–$521 $132
2022 $1,424 $141 $42–$496 $149
2023 $1,780 $149 $45–$519 $160
2024 $1,848 $154 $47–$537 $164
2025 $1,685 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,570 127 payments
  2. AbbVie, Inc. $1,242 75 payments
  3. Amgen Inc. $1,016 73 payments
  4. Novo Nordisk Inc $783 89 payments
  5. Lilly USA, LLC $584 37 payments
  6. GlaxoSmithKline, LLC. $535 43 payments
  7. Amarin Pharma Inc. $419 34 payments
  8. Merck Sharp & Dohme Corporation $418 42 payments
  9. Sumitomo Pharma America, Inc. $377 19 payments
  10. Astellas Pharma US Inc $370 21 payments
  11. Other $3,089 235 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,405 795 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,538 65 payments
  2. BREZTRI $1,483 57 payments
  3. Ozempic $607 75 payments
  4. Repatha Cardiology $577 42 payments
  5. GEMTESA $427 23 payments
  6. REPATHA Cardiovascular $411 29 payments
  7. TRELEGY ELLIPTA $393 29 payments
  8. AIRSUPRA $368 7 payments
  9. JANUVIA $342 37 payments
  10. VRAYLAR $338 18 payments
  11. Other $9,644 738 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

9,002

Median for Internal Medicine: 777

Drug cost

$761,378

Median for Internal Medicine: $73,373

Branded share of claims

18.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 121 $114,758
Ozempic Semaglutide Brand 83 $93,817
Farxiga Dapagliflozin Propanediol Brand 70 $69,565
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 71 $64,918
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 57 $44,711
Xarelto Rivaroxaban Brand 41 $42,829
Repatha Sureclick Evolocumab Brand 54 $38,480
Januvia Sitagliptin Phosphate Brand 19 $21,910
Jardiance Empagliflozin Brand 29 $20,957
Gemtesa Vibegron Brand 21 $19,764

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$34,780

Of which drugs: $501

Medicare patients

84

Average age 74

Services billed

606

45 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 24%
COPD 19%
Atrial fibrillation 14%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90756 Office 15 15 $476

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $316
$316 57 —
Repatha
  • Amgen Inc. $181
$181 54 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $179
$179 70 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $84
  • Lilly USA, LLC $73
$158 29 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

795 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record